Patient-reported outcomes show that datopotamab deruxtecan also improved patient functioning and symptom control compared to chemotherapy
At a senior stage of her career in oncology, Prof. Martine Piccart remains deeply committed in supporting young oncologists in cancer research
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance
Gaps still exist in care and communication for AYA, with failure to address their unique needs
Data from two novel studies further support the feasibility of this approach, although its clinical utility has yet to be determined
A pathological complete response-guided approach enables treatment optimisation in a selected population with HER2-positive breast cancer in the PHERGain-2 study
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
Recent studies support treatment optimisation for improving patients’ quality of life, but its implementation in clinical practice remains limited
Advances in molecular profiling and a greater understanding of the underlying biology are reinforcing the concept of a distinct disease from other ER-positive breast cancers
The 2026 ESMO Breast Cancer Awardee, Daniel F. Hayes, reflects on the future of biomarker research in the field
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.